Novo Nordisk Counters Rival With High-Dose Wegovy Approval

Novo Nordisk Closes Efficacy Gap with Wegovy HD

Novo Nordisk has secured FDA approval for Wegovy HD, a higher-dose version of its flagship weight-loss drug, in a direct strategic move against chief rival Eli Lilly. The new 7.2 mg formulation showed an average weight loss of 20.7% in clinical trials, significantly narrowing the performance gap with Eli Lilly's Zepbound, which averages 22.5% weight loss. This improvement positions Wegovy HD as a more direct competitor, moving beyond the approximate 15% weight loss offered by the original 2.4 mg dose.

The approval provides a crucial boost for Novo Nordisk, whose stock has fallen 28% this year on fears of losing ground in the GLP-1 market. The company had previously issued a troubling forecast for 2026, projecting a revenue decline of as much as 13% due to rising competition. With its stock trading near a 52-week low at a price-to-earnings ratio just over 10, this enhanced product offering aims to reverse negative sentiment and recapture market share.

Oral Drugs Poised to Capture $45B Market by 2030

The entire GLP-1 sector is undergoing a seismic shift toward oral medications, a market segment that analysts forecast could represent a $40 billion to $45 billion annual opportunity by 2030. This transition is driven by strong patient preference for pills over injections and a critical need to address high treatment discontinuation rates. Studies show that nearly 50% of patients stop using injectable GLP-1 drugs within one year, primarily due to gastrointestinal side effects.

The race to dominate the oral market is intense and high-risk. Pfizer's ambitions were dashed on April 14, 2025, when it discontinued its oral candidate, danuglipron, over safety concerns. Now, all eyes are on Eli Lilly, which is expected to receive FDA approval for its oral drug, orforglipron, as soon as April 2026. In anticipation, Eli Lilly has already built a pre-launch inventory valued at $1.5 billion. While effective, trials showed orforglipron had higher rates of adverse side effects compared to Novo Nordisk's semaglutide, highlighting the ongoing trade-off between efficacy and tolerability.

Analysts Warn of Cannibalization and Competitive Risks

Despite the positive clinical data for Wegovy HD, some analysts remain cautious about Novo Nordisk's growth trajectory. Jefferies trimmed its price target for the company, citing uncertainty around pricing and the risk that new oral versions of Wegovy could cannibalize sales from the more established injectable franchise rather than expand the overall customer base.

The impending April launch of Eli Lilly’s oral orforglipron is seen as a significant threat that could decelerate Novo's momentum. Analysts draw parallels to historical patent cliff scenarios, such as AbbVie's with Humira, where valuations compressed significantly. Jefferies noted that such companies have historically traded at 7 to 8 times earnings, suggesting potential downside for Novo Nordisk's stock even after its recent de-rating. A poor launch for oral Wegovy combined with strong data from rivals could trigger further declines.